{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:53:14Z","timestamp":1762113194493,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.joms.2009.04.048","type":"journal-article","created":{"date-parts":[[2010,1,7]],"date-time":"2010-01-07T04:16:40Z","timestamp":1262837800000},"page":"889-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Osteonecrosis of the Jawbones in 2 Osteoporosis Patients Treated With Nitrogen-Containing Bisphosphonates: Osteonecrosis Reduction Replacing NBP With Non-NBP (Etidronate) and Rationale"],"prefix":"10.1016","volume":"68","author":[{"given":"Kouji","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Oizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Funayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2009.04.048_bib1","series-title":"Bone and Mineral Research\/8","first-page":"265","article-title":"Bisphosphonates: Structure-activity relationships and therapeutic implications","author":"Geddes","year":"1994"},{"key":"10.1016\/j.joms.2009.04.048_bib2","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"issue":"suppl","key":"10.1016\/j.joms.2009.04.048_bib3","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: Current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2009.04.048_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2009.04.048_bib5","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2009.04.048_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.joms.2009.04.048_bib7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","article-title":"A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteristics","volume":"29","author":"Pazianas","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.joms.2009.04.048_bib8","first-page":"16","article-title":"A survey of bisphosphonate-related osteomyelitis\/osteonecrosis of the jaw","volume":"53","author":"Shimahara","year":"2007","journal-title":"Jap J Oral Surg"},{"key":"10.1016\/j.joms.2009.04.048_bib10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2009.04.048_bib11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-004-0180-3","article-title":"Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate","volume":"76","author":"Funayama","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joms.2009.04.048_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF00298728","article-title":"Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo","volume":"52","author":"Endo","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joms.2009.04.048_bib13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/sj.bjp.0702367","article-title":"Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate","volume":"126","author":"Endo","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joms.2009.04.048_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.bjp.0702151","article-title":"Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor \u03b1 in mice","volume":"125","author":"Sugawara","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joms.2009.04.048_bib15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0003-9969(00)00039-X","article-title":"Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate","volume":"45","author":"Funayama","year":"2000","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.joms.2009.04.048_bib16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/sj.bjp.0703460","article-title":"Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice","volume":"130","author":"Yamaguchi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joms.2009.04.048_bib17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.taap.2005.09.005","article-title":"Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immunostimulants (IL-1, TNF, and LPS), and its prevention by clodronate","volume":"213","author":"Deng","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.joms.2009.04.048_bib18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1742-7843.2008.00374.x","article-title":"Necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their inhibition by clodronate (a non-NBP) in mice: Potential for utilization of clodronate as a combination drug with an NBP","volume":"104","author":"Oizumi","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.joms.2009.04.048_bib19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2009.04.048_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestation of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.joms.2009.04.048_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00223-002-2156-5","article-title":"Effects of weekly administrations of alendronate + clodronate on young mouse tibia: Localized action at the proximal growth plate","volume":"74","author":"Monma","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joms.2009.04.048_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1742-7843.2005.pto_138.x","article-title":"Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model","volume":"97","author":"Yu","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.joms.2009.04.048_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1476-5381.1996.tb15972.x","article-title":"Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice","volume":"119","author":"Nakamura","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joms.2009.04.048_bib24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","article-title":"Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?","volume":"63","author":"Hellstein","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2009.04.048_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","article-title":"Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment","volume":"7","author":"Migliorati","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2009.04.048_bib26","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.joms.2009.04.048_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.intimp.2006.09.009","article-title":"Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNF\u03b1, macrophages, and T-cells","volume":"7","author":"Deng","year":"2007","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.joms.2009.04.048_bib28","first-page":"294","article-title":"Comparison of the distribution of three bisphosphonates in mice","volume":"65","author":"M\u00f6nkk\u00f6nen","year":"1989","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.joms.2009.04.048_bib29","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.4049\/jimmunol.166.9.5508","article-title":"Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human \u03b3\u03b4 T cells by aminobisphosphonate antigen","volume":"166","author":"Miyagawa","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.joms.2009.04.048_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T-cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.joms.2009.04.048_bib31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1359\/JBMR.0301230","article-title":"Statins prevent bisphosphonate-induced \u03b3, \u03b4-T-cell proliferation and activation in vitro","volume":"19","author":"Thompson","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2009.04.048_bib32","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector \u03b3\u03b4 T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.joms.2009.04.048_bib33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.joms.2009.04.048_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.185.1.91","article-title":"Functional inactivation in the whole population of human V\u03b39\/V\u03b42 T lymphocytes induced by a nonpeptidic antagonist","volume":"185","author":"B\u00fcrk","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.joms.2009.04.048_bib35","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: Differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.joms.2009.04.048_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.jid.5700003","article-title":"Immunosurveillance and immunoregulation by \u03b3\u03b4 T cells","volume":"126","author":"Girardi","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.joms.2009.04.048_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":"The acute phase response after bisphosphonate administration","volume":"41","author":"Adami","year":"1987","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joms.2009.04.048_bib38","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1002\/art.22194","article-title":"A role for geranylgeranylation in interleukin-1 secretion","volume":"54","author":"Mandey","year":"2006","journal-title":"Arthritis Rheumat"},{"key":"10.1016\/j.joms.2009.04.048_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1677\/joe.0.1740007","article-title":"Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone","volume":"174","author":"Newton","year":"2002","journal-title":"J Endocrinol"},{"key":"10.1016\/j.joms.2009.04.048_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbrc.2004.05.145","article-title":"Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis","volume":"320","author":"Gniadecki","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.joms.2009.04.048_bib41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1259\/0007-1285-54-643-592","article-title":"Effects of acute administration of ethane hydroxydiphosphonate (EHDP) on skeletal scintigraphy with technetium-99m methylene diphosphonic acid (Tc-MDP) in the rat","volume":"54","author":"Watt","year":"1981","journal-title":"Br J Radiol"},{"key":"10.1016\/j.joms.2009.04.048_bib42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00003072-198804000-00008","article-title":"False-negative bone imaging due to etidronate therapy","volume":"13","author":"Krasnow","year":"1988","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.joms.2009.04.048_bib43","first-page":"1782","article-title":"Duration of etidronate effect demonstrated by serial bone scintigraphy","volume":"32","author":"Sandler","year":"1991","journal-title":"J Nucl Med"},{"key":"10.1016\/j.joms.2009.04.048_bib44","first-page":"748","article-title":"Skeletal non-visualization in a bone scan secondary to intravenous etidronate therapy","volume":"33","author":"Hommeyer","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.joms.2009.04.048_bib45","first-page":"705","article-title":"The bisphosphonate dilemma","volume":"36","author":"Kayano","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.joms.2009.04.048_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1677\/erc.1.01094","article-title":"Emerging anti-cancer molecular mechanisms of aminobisphosphonates","volume":"13","author":"Caraglia","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.joms.2009.04.048_bib47","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/jnci\/djm029","article-title":"Bisphosphonate therapy for cancer and prevalence of inflammatory jaw conditions","volume":"99","author":"Woo","year":"2007","journal-title":"J Nat Cancer Inst"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239109005503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239109005503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:33:26Z","timestamp":1759509206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239109005503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0278239109005503"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2009.04.048","relation":{},"ISSN":["0278-2391"],"issn-type":[{"type":"print","value":"0278-2391"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteonecrosis of the Jawbones in 2 Osteoporosis Patients Treated With Nitrogen-Containing Bisphosphonates: Osteonecrosis Reduction Replacing NBP With Non-NBP (Etidronate) and Rationale","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2009.04.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}